Apremilast ESTEEM Program Meets Prima...

Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint...

There are 2 comments on the PR-inside.com story from Jan 7, 2013, titled Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint.... In it, PR-inside.com reports that:

Celgene International Sarl, a subsidiary of Celgene Corporation , today announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM 1 & 2 phase III studies.

Join the discussion below, or Read more at PR-inside.com.

Since: Sep 12

Location hidden

#1 Jan 7, 2013
As study found that 10 to 30 percent of psoriasis patient develop psoriatic arthritis, but there may some precautions to avoid these as it causes joint pain, joint stiffness and swelling.

Austin, TX

#2 Jan 15, 2013
To learn more about Apremilast, check out http://www.rxwiki.com/apremilast

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Healthcare Industry Discussions

Title Updated Last By Comments
News Lower Availability of Omega-3 fatty Acids Assoc... 16 hr Nataly 1
News $160B deal to combine Pfizer and Allergan raise... Thu Mite Be 21
News CDC: 'Alarming' increase in STDs Wed Belles Echoes 125
News Pfizer to buy Allergan in $160 billion deal Nov 25 Cordwainer Trout 6
News Press release distribution, EDGAR filing, XBRL,... Nov 23 Buckle Up 1
News Two murdered at Texas campsite are from Oceanside Nov 19 James McMillan 1
News BREAKING NEWS: New details in Katlyn Long inves... (Jun '09) Nov 18 Roach 158
More from around the web